Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03604835 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mucopolysaccharidosis VII Disease Monitoring Program

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 98 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 14 sitesv98
  2. Primary and study completion moved earlier from May 2033 to Apr 2032v97
  3. 2 versions Re-verified since Mar 16, 2026, no change to tracked fieldsv95-v96
  4. Site details revised at 2 of 14 sitesv94
  5. Site details revised at 3 of 14 sitesv93
Show 44 earlier versionsHide 44 earlier versions
  1. 3 versions Re-verified since Sep 3, 2025, no change to tracked fieldsv90-v92
  2. Site details revised at 1 of 14 sitesv89
  3. 9 versions Re-verified since Sep 16, 2024, no change to tracked fieldsv80-v88
  4. Study sites: 15 to 14v79
  5. 8 versions Re-verified since Dec 22, 2023, no change to tracked fieldsv71-v78
  6. Study sites: 14 to 15v70
  7. 2 versions Re-verified since Sep 29, 2023, no change to tracked fieldsv68-v69
  8. Collaborators shortened, about 3 wordsv67 See this version in full on ClinicalTrials.gov ↗
  9. 8 versions Re-verified since Dec 8, 2022, no change to tracked fieldsv59-v66
  10. Study sites: 13 to 14v58
  11. Re-verified, no change to tracked fieldsv57
  12. Enrollment target: 35 to 50v56
  13. 3 versions Re-verified since Jul 8, 2022, no change to tracked fieldsv53-v55
  14. Study sites: 12 to 13v52
  15. 3 versions Re-verified since Mar 8, 2022, no change to tracked fieldsv49-v51
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.
Trial Details
NCT Number NCT03604835
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov